Guardant Health, Inc.

Guardant Health, Inc. has been granted 120 US utility patents between 2017 and 2025, placing Guardant Health, Inc. at rank #3,132 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Guardant Health, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 53.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 109 grants, compared with 11 in the 2015–2019 window — a +891% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Guardant Health, Inc.'s 22.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Guardant Health, Inc. against peers pursuing similar technology classes.